跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FC-11
首页
药物
FC-11
FC-11
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES
申请人: CYTIVA BIOPROCESS R & D AB
优先权: 2014
CN
EP
US
WO
17 件公开
SEPARATION MATRIX
申请人: CYTIVA BIOPROCESS R & D AB
优先权: 2016
CN
EP
US
WO
13 件公开
MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES
申请人: CYTIVA BIOPROCESS R & D AB
优先权: 2016
CN
EP
US
WO
7 件公开
PD-L1 KNOCKOUT CAR-T TRANSGENIC VECTOR FOR SUPPRESSING IMMUNE ESCAPE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME
申请人: SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD
优先权: 2016
CN
EP
US
3 件公开
USE OF BMP RECEPTOR ALK1 INHIBITORS IN OSTEOARTHRITIS THERAPIES
申请人: THE REGENTS OF UNIV OF CALIFORNIA
优先权: 2023
EP
US
WO
3 件公开
Lefty, Lefty derivatives and uses thereof
申请人: ACCELERON PHARMA INC
优先权: 2006
US
3 件公开
IL6R block CAR-T transgenic vector for alleviating CRS, preparation method thereof
申请人: SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD
优先权: 2016
CN
US
2 件公开
Peptides and related molecules that bind to TALL-1
申请人: AMGEN INC
优先权: 2002
US
2 件公开
Growth hormone fusion protein and application thereof
申请人: SHENZHEN KEXING PHARMACEUTICAL CO LTD
优先权: 2021
CN
2 件公开
Substance or composition for the treatment of cancer
申请人: SWARTS JOHANNES CHRISTIAAN
优先权: 2001
US
第 1 / 3 页
上一页
下一页
药物
反馈